EGFR and familial pancreatic carcinoma: Treatment of pancreatic cancer cells with isoflavone compounds (including 70.54% genistein), increased miR-146a expression, causing downregulation of EGFR, MTA-2, IRAK-1, and NF-κB, resulted in inhibition of cell invasion [41].